Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maltodextrin
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Jaguar Licenses Oral Mucositis Product for U.S. Market in Cancer Care
Details : Gelclair will be commercialized by Jaguar Health in the U.S. to alleviate pain from oral lesions, including mucositis and stomatitis.
Brand Name : Gelclair
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Maltodextrin
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?